GlassScriptPhysician profile
Sara May Beard
NPI 1255955043
$1,743.73
in general payments reported to CMS, 2019-2025
20 companies · $1,223 in 2025
The $1,223 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $241 · 2022: $145 · 2023: $67.66 · 2024: $66.53 · 2025: $1,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,357.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $221.88 | 2025 | Ozempic, Wegovy |
| Scpharmaceuticals INC. | $187.81 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $182.44 | 2022-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $152.09 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.39 | 2021 | |
| Alnylam Pharmaceuticals INC. | $121.90 | 2025 | Amvuttra |
| Amgen INC. | $118.81 | 2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $92.83 | 2025 | Camzyos, Eliquis |
| Orthofix Medical, INC. | $85.70 | 2022-2023 | Spinal-Stim, Spinal-Stim |
| Stryker Corporation | $66.53 | 2024 | Adherus Autospray Dural Sealant |
| Astrazeneca Pharmaceuticals LP | $62.56 | 2021-2025 | Wainua |
| Pfizer INC. | $60.18 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $42.41 | 2021 | |
| Esperion Therapeutics, INC. | $40.80 | 2025 | Nexletol |
| Boston Scientific Corporation | $39.80 | 2025 | Watchman Flx |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $38.25 | 2022 | |
| Merck Sharp & Dohme LLC | $35.90 | 2022-2025 | Verquvo |
| Glaxosmithkline, LLC. | $29.47 | 2025 | Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $16.72 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Beard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.